Além da IgE: a emergência do MRGPRX2 como via de ativação mastocitária em reações imediatas a fármacos
Beyond lgE: the emergence of MRGPRX2 as a mediator of lmmediate reactions
Maurício Domingues Ferreira, Paulo Eduardo Silva Belluco
References
1. Kolkhir P, Ali H, Babina M, Ebo D, Sabato V, Elst J et al. MRGPRX2 in drug allergy: what we know and what we do not know. J Allergy Clin Immunol. 2023;151(2):410-2. https://doi.org/10.1016/j.jaci.2022.09.004. PMid:36089079.
2. Baldo BA. MRGPRX2, drug pseudoallergies, inflammatory diseases, mechanisms, and distinguishing MRGPRX2‐ and IgE/FcεRI‐mediated events. Br J Clin Pharmacol. 2023;89(11):3232-46. https://doi.org/10.1111/bcp.15845. PMid:37430437.
3. McNeil BD, Pundir P, Meeker S, Han L, Undem BJ, Kulka M et al. Identification of a mast-cell-specific receptor crucial for pseudoallergic drug reactions. Nature. 2015;519(7542):237-41. https://doi.org/10.1038/nature14022. PMid:25517090.
4. McNeil BD. Minireview: Mas-related G protein-coupled receptor X2 activation by therapeutic drugs. Neurosci Lett. 2021;751:135746. https://doi.org/10.1016/j.neulet.2021.135746. PMid:33610674.
5. Spoerl D, Nigolian H, Czarnetzki C, Harr T. Reclassifying anaphylaxis to neuromuscular blocking agents based on the presumed pathomechanism: IgE-mediated, pharmacological adverse reaction or “innate hypersensitivity”? Int J Mol Sci. 2017;18(6):1223. https://doi.org/10.3390/ijms18061223. PMid:28590439.
6. Elst J, Maurer M, Sabato V, Faber MA, Bridts CH, Mertens C et al. Novel insights on MRGPRX2-mediated hypersensitivity to neuromuscular blocking agents and fluoroquinolones. Front Immunol. 2021;12:668962. https://doi.org/10.3389/fimmu.2021.668962. PMid:34385999.
7. Jiang W, Hu S, Che D, An H, Liu R. A mast-cell-specific receptor mediates iopamidol-induced immediate IgE-independent anaphylactoid reactions. Int Immunopharmacol. 2019;75:105800. https://doi.org/10.1016/j.intimp.2019.105800. PMid:31401386.
8. Azimi E, Reddy VB, Lerner EA. Brief communication: MRGPRX2, atopic dermatitis and red man syndrome. Itch (Phila). 2017;2(1):e5. https://doi.org/10.1097/itx.0000000000000005. PMid:28367504.
9. Alves Jr WX, Ribeiro M, Aun MV, Giavina-Bianchi P. Determinação da reatividade cutânea às quinolonas e fatores associados. Arq Asma Alerg Imunol. 2023;7(4):367-75. https://doi.org/10.5935/2526-5393.20230055.
10. Hsu FI, Bernstein JA, Chhiba KD, Saini SS. Systemic treatments for chronic spontaneous urticaria: anti-IgE and beyond. J Allergy Clin Immunol Pract. 2026;14(2):361-72. https://doi.org/10.1016/j.jaip.2025.11.038. PMid:41654334.
11. Zarabian N, Farah M, Stines A, Friedman A. Targeting mast cells in chronic spontaneous urticaria. Curr Allergy Asthma Rep. 2026;26(1):9. https://doi.org/10.1007/s11882-025-01245-2. PMid:41697480.
Submitted date:
12/14/2025
Accepted date:
05/24/2026
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email